Loading clinical trials...

PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia | Clinical Trials | Clareo Health

COMPLETEDPHASE2

PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia

NCT01521494•Kissei Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

To investigate dose-response efficacy and safety in hemodialysis patients with hyperphosphatemia.

Eligibility

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients age 20 or older, regardless of gender.
•Receiving stable maintenance hemodialysis 3 times a week.
•Patients not having changed their phosphate binder agent dose, for 4 weeks or more before their observation period start.

Exclusion Criteria

•Patients having history of a pronounced brain / cardiovascular disorder.
•Patients having severe gastrointestinal disorders.
•Patients having severe hepatic disorders.

Locations (1)

Japan

Multiple Locations, Japan

Key Dates

Start Date

January 11, 2012

Primary Completion Date

July 3, 2012

Completion Date

July 3, 2012

Last Updated

August 23, 2018

Enrollment

183

ACTUAL participants

Conditions

Chronic Kidney Disease Requiring Hemodialysis

Interventions

PA21

DRUG

PA21

DRUG

PA21

DRUG

PA21

DRUG

Placebo

DRUG

Effect of a Structured Physical Exercise Program on Arteriovenous Fistula Maturation for Hemodialysis in Chronic Kidney Disease Patients

NCT06960304

Chronic Kidney Disease Requiring Hemodialysis

View study

NOT_YET_RECRUITING

Ultrasound Prediction of Successful Balloon Assisted AVF Maturation

NCT06771973

End Stage Renal Disease (ESRD)Chronic Kidney Disease Requiring Hemodialysis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 23, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions